- Home
- / Beam Therapeutics
Beam Therapeutics
Stock Price
$22.2
2024-10-29
Market Capitalization
$1.8 B
2024-10-29
Revenue
$139.7 M
FY, 2025
Beam Therapeutics Summary
Company Summary
- Overview
- Beam Therapeutics is a biotechnology company that develops precision genetic medicines making edits to individual base pairs in the genetic code. The company works on technologies to generate a pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, and modulate the expression or function of disease-causing genes.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- Boston, MA, US | view all locations
- Website
- https://beamtx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
J. Keith Joung, Founder and Inventor
John Evans, Chief Executive Officer and Board Member
Giuseppe Ciaramella, President
Operating MetricsView all
Patents Issued
1
Oct, 2019
Programs
12
Oct, 2019
Trademarks (US)
2
Oct, 2019
LocationsView all
1 location detected
Boston, MA HQ
United States
208 Newbury St
Beam Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $31.7M
- Net income (Q1, 2026)
- ($94.3M)
- Cash (Q1, 2026)
- $288.3M
- EBIT (Q1, 2026)
- ($107.2M)
- Enterprise value
- $1.8B